INT79476

From wiki-pain
(Difference between revisions)
Jump to: navigation, search
(Generated page)
 

Latest revision as of 21:54, 23 September 2012

Context Info
Confidence 0.38
First Reported 1999
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 23
Total Number 25
Disease Relevance 9.50
Pain Relevance 2.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (HLA-DMA) intracellular (HLA-DMA) protein complex assembly (HLA-DMA)
Anatomy Link Frequency
T cells 4
macrophages 2
microglia 2
B cells 1
immune system 1
HLA-DMA (Homo sapiens)
Pain Link Frequency Relevance Heat
Multiple sclerosis 156 99.40 Very High Very High Very High
Bioavailability 129 98.90 Very High Very High Very High
lidocaine 1 97.52 Very High Very High Very High
Potency 42 93.92 High High
Inflammation 96 93.68 High High
ketamine 19 89.04 High High
Neuritis 255 88.64 High High
Spinal cord 69 86.76 High High
cytokine 56 86.24 High High
anesthesia 23 85.36 High High
Disease Link Frequency Relevance Heat
Targeted Disruption 65 99.88 Very High Very High Very High
Neuromyelitis Optica 460 99.62 Very High Very High Very High
Multiple Sclerosis 200 99.40 Very High Very High Very High
Cancer 297 98.20 Very High Very High Very High
Bladder Cancer 76 96.88 Very High Very High Very High
Disease 208 96.44 Very High Very High Very High
Skin Cancer 16 96.20 Very High Very High Very High
Autoimmune Disease 63 95.60 Very High Very High Very High
Adhesions 3 95.20 Very High Very High Very High
Demyelinating Disease 55 94.96 High High

[edit] Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For oral As dosage, solutions of MMA, DMA, AsIII, or AsV (80–100 ?
Gene_expression (solutions) of DMA in MMA
1) Confidence 0.38 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1764129 Disease Relevance 0 Pain Relevance 0.17
The low bioavailability of As in Quest was a result of the high proportion of DMA present in the rice.
Gene_expression (present) of DMA associated with bioavailability
2) Confidence 0.38 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1764129 Disease Relevance 0 Pain Relevance 0.27
Arsenic was present entirely in the inorganic form in Basmati White (Table 1); however, 86 ± 2% of As in Quest was present as DMA (organic As).
Gene_expression (present) of DMA
3) Confidence 0.38 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1764129 Disease Relevance 0.15 Pain Relevance 0
Soluble HLA saliva levels.
Gene_expression (levels) of HLA in saliva
4) Confidence 0.36 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.09 Pain Relevance 0.05
Immune genes, such as TYRO protein tyrosine kinase binding protein (TYROBP), major histocompatibility complex class II DM alpha (HLA-DMA), major histocompatibility complex class II DP beta 1 (HLA-DPB1), and major histocompatibility complex class II DR alpha (HLA-DRA), were likely expressed by infiltrating mononuclear cells, resident microglia, macrophages, and possibly also astrocytes acting as non-professional antigen-presenting cells [83-86].
Gene_expression (expressed) of class II DM alpha in microglia
5) Confidence 0.29 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2567987 Disease Relevance 0.57 Pain Relevance 0
Immune genes, such as TYRO protein tyrosine kinase binding protein (TYROBP), major histocompatibility complex class II DM alpha (HLA-DMA), major histocompatibility complex class II DP beta 1 (HLA-DPB1), and major histocompatibility complex class II DR alpha (HLA-DRA), were likely expressed by infiltrating mononuclear cells, resident microglia, macrophages, and possibly also astrocytes acting as non-professional antigen-presenting cells [83-86].
Gene_expression (expressed) of HLA-DMA in microglia
6) Confidence 0.29 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2567987 Disease Relevance 0.57 Pain Relevance 0
In two cell lines both deficient in NER and one expressing CYP1A2 and NAT2, 2,6-DMA and 3,5-DMA were cytotoxic at dose levels of 100 ?
Gene_expression (cytotoxic) of DMA
7) Confidence 0.14 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0.06 Pain Relevance 0.08
In two cell lines both deficient in NER and one expressing CYP1A2 and NAT2, 2,6-DMA and 3,5-DMA were cytotoxic at dose levels of 100 ?
Gene_expression (2,6) of DMA
8) Confidence 0.14 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0.06 Pain Relevance 0.08
In two cell lines both expressing CYP1A2 and NAT2, but one deficient in NER, 2,6-DMA and 3,5-DMA were cytotoxic and mutagenic at dose levels between 100 ?
Gene_expression (3,5) of DMA
9) Confidence 0.12 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0.07 Pain Relevance 0.09
In our own work, we found that 3,5-DMA, when converted to the acetoxy derivative, produces four distinct adducts in DNA (34).
Gene_expression (produces) of DMA
10) Confidence 0.12 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0 Pain Relevance 0
In two cell lines both expressing CYP1A2 and NAT2, but one deficient in NER, 2,6-DMA and 3,5-DMA were cytotoxic and mutagenic at dose levels between 100 ?
Gene_expression (3,5) of DMA
11) Confidence 0.12 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0.07 Pain Relevance 0.09
We have focused on three members of this group, namely 3-EA, 2,6-DMA and 3,5-DMA, and their N-hydroxy and aminophenol metabolites synthesized as described above.
Gene_expression (synthesized) of DMA
12) Confidence 0.11 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0.08 Pain Relevance 0.04
We have focused on three members of this group, namely 3-EA, 2,6-DMA and 3,5-DMA, and their N-hydroxy and aminophenol metabolites synthesized as described above.
Gene_expression (synthesized) of DMA
13) Confidence 0.11 Published 2010 Journal Carcinogenesis Section Body Doc Link PMC2802674 Disease Relevance 0.08 Pain Relevance 0.04
Immune genes, such as TYRO protein tyrosine kinase binding protein (TYROBP), major histocompatibility complex class II DM alpha (HLA-DMA), major histocompatibility complex class II DP beta 1 (HLA-DPB1), and major histocompatibility complex class II DR alpha (HLA-DRA), were likely expressed by infiltrating mononuclear cells, resident microglia, macrophages, and possibly also astrocytes acting as non-professional antigen-presenting cells [83-86].
Gene_expression (expressed) of class II DM alpha in macrophages
14) Confidence 0.10 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2567987 Disease Relevance 0.57 Pain Relevance 0
Immune genes, such as TYRO protein tyrosine kinase binding protein (TYROBP), major histocompatibility complex class II DM alpha (HLA-DMA), major histocompatibility complex class II DP beta 1 (HLA-DPB1), and major histocompatibility complex class II DR alpha (HLA-DRA), were likely expressed by infiltrating mononuclear cells, resident microglia, macrophages, and possibly also astrocytes acting as non-professional antigen-presenting cells [83-86].
Gene_expression (expressed) of HLA-DMA in macrophages
15) Confidence 0.10 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2567987 Disease Relevance 0.57 Pain Relevance 0
Drugs like sulfamethoxazole (SMX) or lidocaine can be presented to specific human alphabeta+ T cell clones (TCC) by undergoing a noncovalent association with MHC-peptide complexes on HLA-matched APCs.
Gene_expression (complexes) of HLA-matched in T cell associated with lidocaine
16) Confidence 0.08 Published 1999 Journal J. Immunol. Section Abstract Doc Link 9886437 Disease Relevance 0 Pain Relevance 0.14
Further complicating attempts to obtain an HLA match is the fact that HLA expression "tracks with geographical ancestry" [[1], p. 15].
Gene_expression (expression) of HLA
17) Confidence 0.05 Published 2008 Journal Philos Ethics Humanit Med Section Body Doc Link PMC2569955 Disease Relevance 0 Pain Relevance 0
Among these major cellular transmission routes, (1) the type of antigen, (2) the surface molecules (such as HLA) expressed on antigen-presenting cells including macrophages and dendritic cells, and (3) the type of lymphocytes including T cells and B cells will decide the site of inflammation and the size of the lesion.
Gene_expression (expressed) of HLA in T cells associated with inflammation
18) Confidence 0.01 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2964037 Disease Relevance 0.90 Pain Relevance 0.37
Therefore, the site of lesion is determined depending on which antigen is targeted by the immune system. (2) As for the involvement of antigen-presenting cells, classic multiple sclerosis has been associated with the expression of HLA-DR2 on antigen-presenting cells.
Gene_expression (expression) of HLA in immune system associated with multiple sclerosis
19) Confidence 0.01 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2964037 Disease Relevance 0.99 Pain Relevance 0.50
This mechanism may represent a major factor for the down-regulation of HLA class I expression and in the subsequent direct recognition of cancer cells by cytolytic T lymphocytes [61].
Gene_expression (expression) of HLA in T lymphocytes associated with cancer
20) Confidence 0.01 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2212656 Disease Relevance 0.62 Pain Relevance 0

[edit] General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox